Chester County News and Community Website
GENT, Belgium & MALVERN, PA & TOKYO, Japan — H.U. Group Holdings Inc. and its subsidiary Fujirebio have announced the launch of the Lumipulse G sTREM2 assay, a chemiluminescent enzyme …
Fujirebio Launches sTREM2 Assay to Advance Neuroinflammation Research Read More
CHESTER SPRINGS, PA — Indie Lens Pop-Up, presented by ITVS, INDEPENDENT LENS in partnership with Henrietta Hankin Branch Library and WHYY, will host a screening of “Matter of Mind: My …
Matter of Mind: My Alzheimer’s A Screener and Discussion at Henrietta Hankin Branch Library Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has cleared a first-of-its-kind blood test designed to aid in the diagnosis of Alzheimer’s disease, a progressive neurodegenerative disorder affecting …
Groundbreaking Blood Test Offers New Hope for Alzheimer’s Diagnosis Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) unveiled significant progress in its efforts to combat neurodegenerative diseases with updates on its pivotal Phase 3 clinical trial and solid financial …
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress Read More
PHILADELPHIA, PA — The Global CEO Initiative on Alzheimer’s Disease (CEOi) has unveiled an innovative Alzheimer’s Blood Test Performance Database, providing a much-needed tool to help healthcare professionals evaluate and compare …
Global CEO Initiative Launches Alzheimer’s Blood Test Performance Database Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biopharmaceutical company, is set to showcase significant advancements in its treatments for Alzheimer’s disease (AD) and Parkinson’s disease (PD) at the …
Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) will hold a live webcast aimed at providing patients, caregivers, and families with updates on its clinical trials and future plans. The virtual …
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has initiated its pivotal Phase 3 clinical trial evaluating buntanetap as a treatment for early Alzheimer’s disease (AD), marking an important step forward …
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that the U.S. Food and Drug Administration (FDA) has accepted an updated protocol for the company’s pivotal Phase 3 Alzheimer’s (AD) …
FDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s Study Read More
SPRINGFIELD, PA — Springfield, Pa.-based SageLife has raised and donated more than $50,000 to support the Alzheimer’s Association Delaware Valley Chapter.
SageLife Contributes $50,000 to Support Alzheimer’s Association Delaware Valley Chapter Read More